Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Long-Term Debt Repayments (2016)

Integra Lifesciences Holdings' Long-Term Debt Repayments history spans 4 years, with the latest figure at $166000.0 for Q4 2016.

  • For Q4 2016, Long-Term Debt Repayments rose 6.41% year-over-year to $166000.0; the TTM value through Dec 2025 reached $166000.0, down 49.08%, while the annual FY2025 figure was $575.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q4 2016 was $166000.0 at Integra Lifesciences Holdings, up from $160000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $218000.0 in Q2 2015 and bottomed at -$370000.0 in Q4 2014.
  • The 3-year median for Long-Term Debt Repayments is $156500.0 (2015), against an average of $103500.0.
  • The largest annual shift saw Long-Term Debt Repayments soared 142.16% in 2015 before it decreased 10.11% in 2016.
  • A 3-year view of Long-Term Debt Repayments shows it stood at -$370000.0 in 2014, then soared by 142.16% to $156000.0 in 2015, then increased by 6.41% to $166000.0 in 2016.
  • Per Business Quant, the three most recent readings for IART's Long-Term Debt Repayments are $166000.0 (Q4 2016), $160000.0 (Q1 2016), and $156000.0 (Q4 2015).